首页 › 基金 › SILVERARC CAPITAL MANAGEMENT, LLC › SNDX
SILVERARC CAPITAL MANAGEMENT, LLC 对 SNDX 的持仓历史
SYNDAX PHARMACEUTICALS INC · 医疗保健
SILVERARC CAPITAL MANAGEMENT, LLC 在 Q3 2026 的 13F 申报中披露持有 SNDX(SYNDAX PHARMACEUTICALS INC)247,418 股,市值约 US$4.7M,约占其申报组合的 0.59%,在其申报持仓中市值排名第 40 位。 SILVERARC CAPITAL MANAGEMENT, LLC 最近 13 个申报季度中有 11 个季度披露了 SNDX 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
SILVERARC CAPITAL MANAGEMENT, LLC 对 SNDX 的持仓演变
SILVERARC CAPITAL MANAGEMENT, LLC 于 Q3 2023 首次披露 SNDX 持仓:20,000 股(约 US$290K)。 该持仓在 Q1 2025 达到峰值 1,309,224 股,市值约 US$16.1M。 在 11 次申报中,SILVERARC CAPITAL MANAGEMENT, LLC 4 次增持、4 次减持、1 次保持不变。 最近一期申报(Q3 2026)显示持股 247,418 股、市值约 US$4.7M,环比减持 -446,182 股。。 持仓曾出现大幅变动:Q1 2025 增持约 659% (随后一个季度股价下跌 24%)、Q4 2025 增持约 1186% (随后一个季度股价上涨 11%)、Q2 2026 增持约 117% (随后一个季度股价下跌 14%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 20.00K | $290.40K | 新进 |
| Q2 2024 | 370.00K | $7.60M | 新进 |
| Q3 2024 | 378.75K | $7.29M | 增持 |
| Q4 2024 | 172.40K | $2.28M | 减持 |
| Q1 2025 | 1.31M | $16.08M | 增持 |
| Q2 2025 | 50.00K | $468.00K | 减持 |
| Q3 2025 | 50.00K | $769.50K | 持有 |
| Q4 2025 | 642.90K | $13.51M | 增持 |
| Q1 2026 | 320.00K | $7.48M | 减持 |
| Q2 2026 | 693.60K | $15.16M | 增持 |
| Q3 2026 | 247.42K | $4.65M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 SNDX 与 13F 数据
SNDX(SYNDAX PHARMACEUTICALS INC)属于医疗保健行业。我们追踪的基金中还有 40 只申报持有 SNDX,申报仓位最大的包括:Kynam Capital Management, LP (US$176.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$82.6M), Eversept Partners, LP (US$61.2M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 SNDX 的基金
- Kynam Capital Management, LP 8.05M 股 · $175.99M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.78M 股 · $82.63M · Q2 2026
- Eversept Partners, LP 2.80M 股 · $61.17M · Q2 2026
- KINGDON CAPITAL MANAGEMENT, L.L.C. 2.50M 股 · $54.65M · Q2 2026
- Elmind Capital, LP 1.85M 股 · $40.55M · Q2 2026
- Soleus Capital Management, L.P. 1.63M 股 · $35.59M · Q2 2026
- ORBIMED ADVISORS LLC 1.54M 股 · $33.71M · Q2 2026
- MPM BioImpact LLC 1.33M 股 · $29.15M · Q2 2026
- Catalio Capital Management, LP 1.22M 股 · $26.58M · Q2 2026
- Prosight Management, LP 1.20M 股 · $26.23M · Q2 2026
- Aisling Capital Management LP 1.32M 股 · $24.76M · Q3 2026
- Trails Edge Capital Partners, LP 1.11M 股 · $24.26M · Q2 2026
更多关于 SILVERARC CAPITAL MANAGEMENT, LLC
常见问题
How long has SILVERARC CAPITAL MANAGEMENT, LLC held SNDX?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed SNDX holdings in 11 of the last 13 reported quarters, going back to Q3 2023.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in SNDX?
As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 247.42K shares of SNDX (SYNDAX PHARMACEUTICALS INC), valued at $4.65M, representing 0.59% of its reported portfolio and ranking #40.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling SNDX?
In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC reduced its position in SNDX. The position peaked in Q1 2025 at 1.31M shares.
Which other funds hold SNDX?
Other major institutional holders of SNDX include Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Eversept Partners, LP, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.